The future of combining inhaled drugs for COPD

► Single therapy with LAMAs, LABAs or ICS often fail to control symptoms in chronic obstructive pulmonary disease (COPD). ► Increasing evidence supports the use of two or all three drug classes in COPD. ► Combination inhalers improve compliance and evaluation of efficacy and safety. ► Several novel molecules are being developed for once daily combination treatment. ► Better phenotyping of COPD is likely to improve individualization of treatment.